Alembic Pharma gains on getting USFDA`s final nod for Icatibant Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Alembic Pharmaceuticals is currently trading at Rs. 894.90, up by 4.80 points or 0.54% from its previous closing of Rs. 890.10 on the BSE.
The scrip opened at Rs. 905.00 and has touched a high and low of Rs. 917.50 and Rs. 891.75 respectively. So far 2464 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 600.65 on 23-Jun-2023.
Last one week high and low of the scrip stood at Rs. 925.55 and Rs. 880.30 respectively. The current market cap of the company is Rs. 17572.74 crore.
The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 19.84% and 10.54% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Firazyr Injection, 30 mg/3 mL (10 mg/mL), of Takeda Pharmaceuticals U.S.A., Inc. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
This is the first peptide product approval from the USFDA received by the Company. Icatibant Injection has an estimated market size of $112 million for twelve months ending Mar 2024 according to IQVIA. The company has a cumulative total of 205 ANDA approvals (177 final approvals and 28 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
